首页 | 本学科首页   官方微博 | 高级检索  
     

晚期非小细胞肺癌组织中ERCC1、RRM1表达水平与含铂治疗方案疗效及预后相关性分析
引用本文:王鑫,支修益. 晚期非小细胞肺癌组织中ERCC1、RRM1表达水平与含铂治疗方案疗效及预后相关性分析[J]. 解剖与临床, 2013, 0(3): 186-190
作者姓名:王鑫  支修益
作者单位:首都医科大学宣武医院胸外科首都医科大学肺癌诊疗中心,北京市100053
摘    要:目的:探讨ERCC1及RRM1的表达在预测晚期非小细胞肺癌含铂治疗方案疗效及预后中的作用。方法:用免疫组织化学的方法检测124例ⅢB和Ⅳ期非小细胞肺癌患者的石蜡包埋活检组织标本中ERCC1和RRM1的表达水平,并分析其与临床病理特征以及疗效、预后的相关性。124例均为接受以铂类为基础的三代药物联合化疗的初治患者。结果:ERCC1、RRM1表达阳性者分别为43例(35%)和50例(40%)。ERCC1及RRM1的表达与疗效相关,ERCC1表达阴性者疗效达PR的患者(54%)明显高于阳性者(33%),差异有统计学意义(P=0.022)。同样,RRM1表达阴性患者疗效为PR的明显高于RRM1阳性者(53%VS34%,P=0.042)。ERCC1和RRM1同时阴性表达者的中位生存时问明显长于同时阳性表达者(11.7个月VS9.2个月,P=0.025),多因素分析表明,ERCC1为独立的预后预测因素(P=0.0066)。结论:ERCC1的表达与晚期非小细胞肺癌预后及含铂治疗方案疗效相关。

关 键 词:ERCC1  RRM1  非小细胞肺癌  含铂方案  疗效  预后

Expression of ERCCI, RRMI in Advanced Non - Small Cell Lung Cancer and Therapeutic Effect of Platinum -based Chemotherapy as well as Its Prognosis
Affiliation:WANG Xin, ZHI Xiu - yi. Department of Thoracic Surgery, Xuanwu hospital, Capital Medical University Beijing 100053, China
Abstract:Objective:To determine a role of ERCC1 and RRM1 expression in predicting response and survival in Chinese patients with advanced stage non -small cell lung cancer(NSCLC) treated with platinum - based chemotherapy. Methods: Formalin - fixed, paraffin - embedded biopsy tissues were retrospectively obtained from 124 advanced( stage HI b and IV ) NSCLC patients treated with platinumbased chemotherapy. Protein expression levels of ERCC1 and RRM1 were determined by immunobistochemistry(IHC). Associations between expression of ERCC1 and RRM1 and clinic- pathologic parameters were analyzed. Results:The study showed that ERCC1 and RRM1 expression was detected in 43(35% ) and 50(40% ) of the 124 tumor samples respectively. Expression of ERCC1 and RRM1 was associated with tumor response. Fifty - four percent patients whose tumors did not express ERCC1 had partial response(PR) compared with 33% whose tumors expressed the protein(P =0.022). Similarly, 53% patients whose tumor did not express RRM1 had PR compared with 34% whose tumors expression the protein(P = 0.042). Further, patients whose tumors lacked ERCC1 but not RRM1 expression had a longer median survival time than those tumors expressed ERCC1 (11.7 months vs 9.2 months ; P = 0. 025 ) , which was independent of other prognostic factors ( P = 0. 0066 ). Conclusions : Tumor ERCC1 expression is associated with tumor response and patients' survival in Chinese advanced NSCLC pa- tients treated with platinum - based regimen and may serve as a biomarker in predicting tumor response and clinical outcome in the patient population.
Keywords:ERCC1  RRM1  NSCLC  Platinum - based chemotherapy  Therapeutic effect  Prognosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号